Megadeals keep in­vest­ments up in lifesci’s Q1, but the tem­po con­tin­ues to slow for biotech

The mon­ey train in biotech­nol­o­gy has slowed down.

In an­oth­er clear sign that ven­ture in­vestors and crossovers are tap­ping the brakes, the new Mon­eyTree Re­port shows that Q1 in­vest­ing in biotech fell to $887,310,000, a sig­nif­i­cant drop from the $1.3 bil­lion the re­port reg­is­tered for the same pe­ri­od in 2016.

But with the help of a cou­ple of megadeals — in­clud­ing a $900 mil­lion wa­ger on a new di­ag­nos­tics play­er — once you step back and take a broad­er look at the life sci­ences busi­ness the over­all num­ber for the in­dus­try, in­clud­ing de­vices, swelled to $3.4 bil­lion, a sig­nif­i­cant gain over the first three months of 2016.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER